Voss Capital, LLC Cognition Therapeutics Inc Transaction History

Voss Capital, LLC

$1.15 Billion
Q4 2024

A detailed history of Voss Capital, LLC transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Voss Capital, LLC holds 500,000 shares of CGTX stock, worth $195,000. This represents 0.03% of its overall portfolio holdings.

Number of Shares

500,000

Holding current value

$195,000

% of portfolio

0.03%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.38 - $0.84 $190,000 - $420,000	500,000 New	500,000 $375,000
Q2 2023 Jul 28, 2023	SELL	$1.56 - $3.38 $155,611 - $337,158	-99,751 Reduced 62.35%	60,222 $110,000
Q1 2023 May 12, 2023	SELL	$1.51 - $2.3 $10,464 - $15,938	-6,930 Reduced 4.15%	159,973 $316,000
Q4 2022 Feb 13, 2023	SELL	$1.17 - $3.51 $61,070 - $183,211	-52,197 Reduced 23.82%	166,903 $350,000
Q3 2022 Nov 02, 2022	SELL	$1.63 - $3.6 $147,306 - $325,339	-90,372 Reduced 29.2%	219,100 $416,000
Q2 2022 Aug 09, 2022	BUY	$1.5 - $3.45 $424,549 - $976,463	283,033 Added 1070.51%	309,472 $653,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $134,838 - $343,178	26,439 New	26,439 $167,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

13.4M

Call Options Held

Put Options Held

Bios Capital Management, LP Fort Worth, TX

6M
Shares

$2.34 Million
4.39% of portfolio
Pathstone Family Office, LLC Englewood, NJ

2.21M
Shares

$860,097
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.24M
Shares

$483,431
0.0% of portfolio
Sigma Planning Corp Ann Arbor, MI

614K
Shares

$239,651
0.01% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

500K
Shares

$195,000
0.0% of portfolio

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $8.86M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voss Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voss Capital, LLC with notifications on news.

Account